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LETTER TO THE EDITOR
Is Adiponectin Related to Orofacial Clefts? 
 
 
Dear Editor, 
Orofacial clefts are the most common congenital 
anomalies  of the head and neck and its incidence 
ranges from 1/500 to 1/2000 live births, depending on 
populations.
1 Etiology of these anomalies is multifac-
torial and includes both environmental and genetic 
factors. Many teratogenic agents and factors in preg-
nancy are claimed to cause clefting, such as maternal 
smoking and hypoxia
2 and diabetes mellitus.
3,4 The 
pivotal role of diabetes mellitus and maternal obesity 
on the incidence of orofacial clefts has been discussed 
previously.
5 
Adiponectin is 244-amino acid collagen-like poly-
peptide that is secreted by adipocytes and acts as an 
anti-inflammatory hormone and insulin sensitizer.
6 
Adiponectin exists in at least two forms, low molecular 
weight oligomer that is hexamers (two trimers) and 
high molecular weight oligomer consisting of four to 
six tirmers.
7 Plasma concentration of this polypeptide 
in human blood ranges from 3 to 30 µg/ml and ac-
counts for 0.05% of total plasma protein.
8  
Findings from animal studies and metabolic studies 
in human suggests that adiponectin has different prop-
erties, such as suppression of hepatic gluconeogenesis, 
stimulation of fatty acid oxidation in the liver, glucose 
uptake in skeletal muscle and stimulation of insulin 
secretion.
8,9 According to most of the studies in differ-
ent populations, higher adiponectin level is associated 
with a lower risk of diabetes
10 and low plasma level of 
adiponectin is associated with increased insulin re-
sistance both in children and adults.
11 
As we know, diabetes mellitus is one of the major 
risk factors of orofacial clefts.
3 So it is suggested that 
lower adiponectin levels in diabetic pregnant women 
takes part as a risk factor  for orofacial clefts. This 
hypothesis could be assessed by screening pregnant 
women with diabetes mellitus for serum adiponectin 
level, and then investigating the incidence of cleft lip 
and/or palate in their children in comparison to con-
trol group. 
According to our knowledge, diabetes mellitus is 
one of the important risk factors of orofacial clefts.
3 
Adiponectin is secreted by adipocytes and increases 
insulin sensitivity. Higher levels of adiponectin are 
associated with lower risk of diabetes mellitus and the 
dose-response relation is consistent. If the association 
between adiponectin level and orofacial clefts in 
pregnant mothers can be verified, then one of the ma-
jor risk factors of orofacial clefts could be achieved. 
These  evidences suggest adiponectin level can be 
used as a screening marker for early diagnosis of obe-
sity related abnormalities. 
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